九州通：子公司获得化学原料药上市申请批准通知书

Core Viewpoint - The approval of the listing application for Glycopyrrolate by the National Medical Products Administration is expected to positively impact the future development of the company's pharmaceutical industrial business and enhance its competitiveness in the active pharmaceutical ingredient market [1] Group 1: Company Developments - The company's subsidiary, Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd., received the approval notice for the listing application of Glycopyrrolate on October 16, 2025 [1] - Glycopyrrolate is a quaternary ammonium anticholinergic drug used for treating gastric and duodenal ulcers, chronic gastritis, and for maintaining bronchial dilation in adult patients with chronic obstructive pulmonary disease [1] - The approval will enrich the company's product line and strengthen its market position in the active pharmaceutical ingredient sector [1]